Carregant...
Antibody-drug conjugates: Present and future
Antibody-drug conjugates (ADCs) are becoming an increasingly important sub-class of antibody-related therapeutics. Two ADCs, brentuximab vedotin (Adcetris®) and ado-trastuzumab emtansine (Kadcyla®), were recently approved for marketing both by the US Food and Drug Administration (FDA) and the Europe...
Guardat en:
| Publicat a: | MAbs |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7098595/ https://ncbi.nlm.nih.gov/pubmed/24423577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.27436 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|